Functional characteristics and clinical effectiveness of platelet concentrates treated with riboflavin and ultraviolet light in plasma and in platelet additive solution

Vox Sanguinis

Volumn 110, Issue 3, 2016, Pages 244-252

  Ignatova, A A ^a   Karpova, O V ^a   Trakhtman, P E ^a   Rumiantsev, S A ^a   Panteleev, M A ^a  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

Author keywords

Pathogen inactivation; Platelet concentrates; Platelet function; Platelet transfusion; SSP+

Indexed keywords

C REACTIVE PROTEIN; GLYCOPROTEIN IIB; GLYCOPROTEIN IIIA; GLYCOPROTEIN VI; PADGEM PROTEIN; PHOSPHATIDYLSERINE; RIBOFLAVIN; THROMBOCYTE CONCENTRATE; FIBRINOGEN RECEPTOR;

APHERESIS; ARTICLE; BLOOD TRANSFUSION REACTION; CLINICAL EFFECTIVENESS; CLINICAL STUDY; CONTROLLED STUDY; FLOW CYTOMETRY; GAMMA RADIATION; HUMAN; HUMAN CELL; MITOCHONDRIAL MEMBRANE POTENTIAL; PATHOGEN REDUCTION SYSTEM; PLASMA; PRIORITY JOURNAL; THROMBOCYTE; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION; THROMBOCYTE TRANSFUSION; ULTRAVIOLET RADIATION; BLOOD; BLOOD STORAGE; CYTOLOGY; DRUG EFFECTS; RADIATION RESPONSE; THROMBOCYTOPHERESIS;

BLOOD PLATELETS; BLOOD PRESERVATION; FLOW CYTOMETRY; HUMANS; MEMBRANE POTENTIAL, MITOCHONDRIAL; P-SELECTIN; PHOSPHATIDYLSERINES; PLATELET ACTIVATION; PLATELET COUNT; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; PLATELET TRANSFUSION; PLATELETPHERESIS; RIBOFLAVIN; ULTRAVIOLET RAYS;

EID: 84949658107     PISSN: 00429007     EISSN: 14230410     Source Type: Journal    
DOI: 10.1111/vox.12364     Document Type: Article

References (28)

1. Holbro A, Infanti L, Sigle J, et al.: Platelet transfusion: basic aspects. Swiss Med Wkly 2013; 143:w13885
2. Liebman HA: Thrombocytopenia in cancer patients. Thromb Res 2014; 133:S63-S69
3. Stramer SL: Current perspectives in transfusion-transmitted infectious diseases: emerging and re-emerging infections. ISBT Sci Ser 2013; 9:30-36
4. Dodd RY: Emerging pathogens and their implications for the blood supply and transfusion transmitted infections. Br J Haematol 2012; 159:135-142
5. Brown CJ, Navarrete CV: Clinical relevance of the HLA system in blood transfusion. Vox Sang 2011; 101:93-105
6. Pelszynski MM, Moroff G, Luban NLC, et al.: Effect of gamma irradiation of red blood cell units on T-cell inactivation as assessed by limiting dilution analysis: implications for preventing transfusion-associated graft-versus-host disease. Blood 1994; 83:1683-1689
7. Mundt JM, Rouse L, Van den Bossche J, et al.: Chemical and biological mechanisms of pathogen reduction technologies. Photochem Photobiol 2014; 90:957-964
8. Schlenke P: Pathogen inactivation technologies for cellular blood components: an update. Transfus Med Hemother 2014; 41:309-325
9. Fast LD, Dileone G, Li J, et al.: Functional inactivation of white blood cells by Mirasol treatment. Transfusion 2006; 46:642-648
10. Fast LD, Dileone G, Marschner S: Inactivation of human white blood cells in platelet products after pathogen reduction technology treatment in comparison to gamma irradiation. Transfusion 2011; 51:1397-1404
11. Reddy HL, Dayan AD, Cavagnaro J, et al.: Toxicity testing of a novel riboflavin-based technology for pathogen reduction and white blood cell inactivation. Transfus Med Rev 2008; 22:133-153
12. Middelburg RA, Roest M, Ham J, et al.: Flow cytometric assessment of agonist-induced P-selectin expression as a measure of platelet quality in stored platelet concentrates. Transfusion 2013; 53:1780-1787
13. Galan AM, Lozano M, Molina P, et al.: Impact of pathogen reduction technology and storage in platelet additive solutions on platelet function. Transfusion 2011; 51:808-815
14. Johnson L, Winter KM, Reid S, et al.: The effect of pathogen reduction technology (Mirasol) on platelet quality when treated in additive solution with low plasma carryover. Vox Sang 2011; 101:208-214
15. Reid S, Johnson L, Woodland N, et al.: Pathogen reduction treatment of buffy coat platelet concentrates in additive solution induces proapoptotic signaling. Transfusion 2012; 52:2094-2103
16. Castrillo A, Cardoso M, Rouse L: Treatment of buffy coat platelets in platelet additive solution with Mirasol pathogen reduction technology system. Transfus Med Hemother 2013; 40:44-48
17. Ostrowski SR, Bochsen L, Salado-Jimena JA, et al.: In vitro cell quality of buffy coat platelets in additive solution treated with pathogen reduction technology. Transfusion 2010; 50:2210-2219
18. Ramström S, Rånby M, Lindahl TL: Platelet phosphatidylserine exposure and procoagulant activity in clotting whole blood-different effects of collagen, TRAP and calcium ionophore A23187. Thromb Haemost 2003; 89:132-141
19. Topalov NN, Kotova YN, Vasil'ev SA, et al.: Identification of signal transduction pathways involved in the formation of platelet subpopulations upon activation. Br J Haematol 2012; 157:105-115
20. Schiffer CA, Anderson KC, Bennett CL, et al.: Platelet transfusion for patients with cancer: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol 2001; 19:1519-1538
21. Cookson P, Thomas S, Marschner S, et al.: In vitro quality of single-donor platelets treated with riboflavin and ultraviolet light and stored in platelet storage medium for up to 8 days. Transfusion 2012; 52:983-994
22. Picker SM, Tauszig ME, Gathof BS: Cell quality of apheresis-derived platelets treated with riboflavin-ultraviolet light after resuspension in platelet additive solution. Transfusion 2012; 52:510-516
23. Abonnenc M, Sonego G, Crettaz D, et al.: In vitro study of platelet function confirms the contribution of the ultraviolet B (UVB) radiation in the lesions observed in riboflavin/UVB-treated platelet concentrates. Transfusion 2015; 55:2219-2230.
24. Zeddies S, De Cuyper IM, Van Der Meer PF, et al.: Pathogen reduction treatment using riboflavin and ultraviolet light impairs platelet reactivity toward specific agonists in vitro. Transfusion 2014; 54:2292-2300
25. Osman A, Hitzler WE, Meyer CU, et al.: Effects of pathogen reduction systems on platelet microRNAs, mRNAs, activation, and function. Platelets 2015; 26:154-163
26. Van Aelst B, Feys HB, Devloo R, et al.: Riboflavin and amotosalen photochemical treatments of platelet concentrates reduce thrombus formation kinetics in vitro. Vox Sang 2015; 108:328-339
27. Perez-Pujol S, Tonda R, Lozano M, et al.: Effects of a new pathogen-reduction technology (Mirasol PRT) on functional aspects of platelet concentrates. Transfusion 2005; 45:911-919
28. Picker SM, Steisel A, Gathof BS: Cell integrity and mitochondrial function after Mirasol-PRT treatment for pathogen reduction of apheresis-derived platelets: results of a three-arm in vitro study. Transfus Apher Sci 2009; 40:79-85